Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

OBJECTIVE: The use of ipilimumab plus anti-PD-1 has recently been shown to significantly improve the survival of patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy. The study assessed the cost-effectiveness of ipilimumab plus anti-PD-1 therapy in this population from the US paye...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Ye, Zeng, Xiaohui, Peng, Liubao, Liu, Qiao, Yi, Lidan, Luo, Xia, Li, Sini, Wang, Liting, Qin, Shuxia, Wan, Xiaomin, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630699/
https://www.ncbi.nlm.nih.gov/pubmed/34858820
http://dx.doi.org/10.3389/fonc.2021.743765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630699/
https://www.ncbi.nlm.nih.gov/pubmed/34858820
http://dx.doi.org/10.3389/fonc.2021.743765

Ejemplares similares